Amgen to delay earnings report for study results
- Share via
From Reuters
Amgen Inc. said it would delay reporting first-quarter earnings until April 23 to include data from an anxiously anticipated study of its Aranesp anemia drug among patients with small-cell lung cancer.
The Thousand Oaks-based biotech company said it would include “top-line results,” meaning important but limited data, from the “145 study,” which involved patients who had the less common form of lung cancer and were undergoing chemotherapy.
